SABCS Co-Director Virginia G. Kaklamani, MD, joins Erika Hamilton, MD, of Sarah Cannon Research Institute, and Komal Jhaveri, MD, of Memorial Sloan Kettering Cancer Center to discuss when endocrine therapy should change in HR-positive metastatic breast cancer and what evidence should guide that decision.